[pubmed] CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients
Posté : 18 avr. 2021 12:00
J Neuroimmunol. 2021 Apr 9;355:577571. doi: 10.1016/j.jneuroim.2021.577571. Online ahead of print.
ABSTRACT
The study aims to identify clinical factors affecting tacrolimus blood trough concentration (C0) in myasthenia gravis (MG) patients and to optimize the initial dose of tacrolimus in MG treatment. A total of 103 MG patients participated in this study, and their clinical factors, medication regimens, C0 values and CYP3A5*3 polymorphisms were collected in detail. We used a linear mixed model to analyze the effect of multiple factors on the dosage-weighted C0 (C0:D) and performed subgroup analyses to investigate the consistency of correlations between influencing factors and the C0:D ratios. Among all factors, CYP3A5*3 polymorphism and age showed a strong positive correlation with C0:D ratios. The C0:D ratios (ng/ml·mg-1) were higher for CYP3A5*3/*3 than for CYP3A5*1 (mean difference: 1.038, 95% confidence interval [CI]: 0.820-1.256, P-value
Source: https://pubmed.ncbi.nlm.nih.gov/3386628 ... 4&v=2.14.3